Curaleaf Aurora Acquisition Bid: Offer Terms, Process and Implications

Executive summary

Curaleaf Holdings filed an update to its offering circular on October 6, 2026, folding its previously announced increased offer for Aurora Cannabis into the formal bid documents. Cannabis Business Times reported the filing the same day. The update turns a headline price increase into a legally operative amendment that Aurora shareholders can tender against.

The bid pairs the largest U.S. multi-state operator (MSO) by revenue with one of the best-known Canadian licensed producers. Aurora is a leader in international medical cannabis, with a meaningful position in Germany. Curaleaf is a U.S. plant-touching operator that has spent years building a European medical platform. The strategic logic is a combined company spanning U.S. retail and cultivation, Canadian production and European medical supply.

This page is the evergreen reference for the bid. It covers the structure of a cross-border cannabis takeover, the Canadian securities rules that govern a bid and its amendments, and the regulatory gates the deal must clear. It also covers the business logic for both sides and the scenarios from here.

One caution up front: the headline filing is a procedural document, and this foundation does not restate the bid's price or consideration mix. CannIntel will append dated update sections as terms, deadlines, board responses and regulatory milestones are confirmed against primary filings on SEDAR+. Readers making capital decisions should read the circular itself.

Why this matters

A completed Curaleaf–Aurora deal would be one of the largest cross-border cannabis combinations on record and a test of whether U.S. MSOs can use their balance sheets to buy their way into federally legal international markets. The stakes reach shareholders, patients, regulators and competitors.

Stakeholders

• Aurora shareholders choose whether to tender, and an increased offer resets the economics of that choice. Many hold shares after years of dilution, impairments and a 1-for-12 share consolidation in 2023.
• Curaleaf shareholders bear the integration, financing and dilution risk if consideration includes equity.
• Medical patients in Germany, Canada, Poland, Australia and the UK depend on import and domestic supply chains where Aurora is a significant name.
• Competing operators such as Canopy Growth, Tilray Brands and other MSOs must decide whether to counter-bid or reposition.
• Regulators in Canada, the United States and Europe each hold a piece of the approval process.

Scale

Curaleaf operates in many U.S. states, including Florida, New York, New Jersey, Pennsylvania, Massachusetts, Illinois and Arizona. Its trading venues are the Toronto Stock Exchange and the OTCQX, not a U.S. national exchange. Aurora trades on the TSX and Nasdaq, which makes it a rare publicly listed target with access to U.S. institutional capital markets. The combination would test how those two listing worlds fit together.

Why the amendment matters

Under Canadian take-over bid rules, an increased price is not binding until the bidder formally varies the bid and delivers the revised documents to shareholders. Today's filing is that step. It also restarts clocks that determine when shareholders can tender, when the bid can close, and how much time Aurora's board has to respond.

Background and history

The bid is the product of a decade in which Canadian producers pioneered public-market cannabis capital, U.S. MSOs built the larger profit pool behind federal prohibition, and both models ran into the limits of their structures. The timeline below shows how the two companies arrived at this point.

2010–2014: Two founding stories

Curaleaf traces its origins to 2010 and the early U.S. state medical programs, building licensed vertically integrated operations one state at a time. Aurora was founded in 2013 in Alberta and went public on the TSX Venture Exchange in 2014 as Canada's licensed-producer regime took shape under the Marihuana for Medical Purposes Regulations. The two companies grew in separate regulatory systems. Canada built a national medical framework, while the United States left the question to states in conflict with federal law.

2018: Legalization, mega-deals and public listings

Canada legalized adult-use cannabis nationally on October 17, 2018 under the Cannabis Act (S.C. 2018, c. 16). That year Aurora completed its landmark MedReleaf acquisition, announced at roughly C$3.2 billion, and bought CanniMed. It also listed on the NYSE, later moving to Nasdaq. Curaleaf listed on the Canadian Securities Exchange in 2018 and used that access to fund a rapid acquisition program across U.S. states. The same year marked the peak of cross-border capital enthusiasm.

2019–2022: Overbuild, write-downs and restructuring

Canada's adult-use market suffered from oversupply, slow retail rollout and price compression. Aurora recorded large impairments, shut or idled facilities, cut staff and refocused on medical and international sales. It later consolidated its shares 12-for-1 in 2023. In the United States, MSOs such as Curaleaf kept expanding through limited-license states but faced the cost of Section 280E of the Internal Revenue Code (26 U.S.C. § 280E), which denies ordinary business deductions to businesses trafficking in Schedule I or II substances. Curaleaf also built a European platform, including its acquisition of the UK's EMMAC Life Sciences, which placed it in direct competition with Aurora in European medical markets.

2023–2025: Pivot to medical, to Germany and to federal reform

Aurora repositioned around international medical cannabis, with Germany as the anchor market, alongside Canadian medical and a cost-reduced Canadian adult-use business. Germany's cannabis policy changes in 2024, including the partial legalization law that took effect April 1, 2024, shifted the medical-import landscape and made European supply scale more valuable. In the United States, the federal rescheduling debate moved forward. The DEA had an open proposed rule (NPRM) to move marijuana to Schedule III under the Controlled Substances Act (21 U.S.C. § 812), and a December 2025 presidential executive order directed agencies to accelerate it. Rescheduling would change the 280E math for every U.S. operator and reshape how acquirers value U.S. assets.

2026: The bid

Curaleaf publicly pursued Aurora and then announced an increased offer. On October 6, 2026, it filed an update to its offering circular incorporating that increase, according to Cannabis Business Times. The sequence is a standard feature of contested bids: an initial approach, a price move to attract tenders or force a board response, and a formal document revision to make the new terms effective.

Key players

The bid involves two operating companies, their boards and shareholders, and a set of regulators and rival bidders who can each shape the outcome.

Curaleaf Holdings

Curaleaf is a vertically integrated cannabis company with a large U.S. retail and wholesale footprint. It is headquartered in Massachusetts and incorporated in British Columbia, and it trades on the TSX and OTCQX. Boris Jordan serves as chairman and chief executive. The company has used acquisitions throughout its history and has built an international arm covering Europe. For Curaleaf, Aurora offers a Canadian licensed-producer platform, listed-equity currency in the Nasdaq market and a larger German medical presence.

Aurora Cannabis

Aurora is an Edmonton-based licensed producer listed on the TSX and Nasdaq, with Miguel Martin as chief executive. It runs Canadian medical and adult-use businesses, an international medical export platform and Australian and European distribution. Its strengths are pharmaceutical-grade cultivation, regulatory licences in multiple jurisdictions and recognized medical brands. Its past is a long record of restructuring after its 2018 growth-by-acquisition phase.

Aurora's board and special committee

In a contested bid, the target board's duties are central. Under Canadian practice the board is expected to evaluate the offer, consult financial advisors, consider alternatives and make a recommendation to shareholders, typically in a directors' circular. Whether it recommends acceptance, rejection or neutrality will shape tender behavior.

Aurora shareholders and institutions

Aurora's register includes retail holders, funds and institutions. Because Canadian rules require a minimum tender condition, the bid cannot close unless more than 50% of outstanding shares held by independent holders are tendered. That puts the decision in the hands of the broad shareholder base.

Potential rival bidders

Canadian bid law permits competing offers. Larger Canadian producers such as Canopy Growth and Tilray Brands, and other well-capitalized MSO